At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- ALTO-207 (drug), Placebo (drug)
- How long the study runs
- Study runs about 19 months (dates as stated)
- About the drug or intervention
- ALTO-207 — drug: ALTO-207 BID · Placebo — drug: Matching Placebo
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a medicine called ALTO-207 in adults aged 18 to 75 with treatment-resistant depression (TRD), which means depression that has not improved after trying at least two antidepressant treatments. The study is run by a company called Alto Neuroscience. Not stated — ask the trial team about the aims and how the medicine works.
Who can take part
- Adults aged 18 to 75, of any gender
- A diagnosis of moderate to severe major depressive disorder (MDD) without psychotic symptoms in the current episode
- Depression that has not improved by at least half after 2 to 5 antidepressant treatments, including the current one
- Currently taking a steady dose of 1 or 2 oral antidepressants
Who may not be able to
- An unstable medical condition
- Use of medicines not allowed in the study, or a substance use disorder
- Bipolar disorder, a psychotic disorder, or psychotic symptoms
- Significant post-traumatic stress disorder (PTSD) symptoms now, or PTSD in the past
- Serious problems with controlling impulses at the moment
- Past allergic reaction to ALTO-207 or anything in it
- Taking part now, or recently, in another clinical trial for mental illness involving a new product or device
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about visits, duration, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 75 Years
- Who
- All
- Number of participants
- 178
- Started
- 2026-05
- Last checked
- 2026-04
Plain English Summary
What is this study?
- • Testing a new treatment for treatment-resistant depression (trd)
- • Phase2 - 178 participants
- • The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD
Who can take part?
- • Ages 18 Years to 75 Years
- • Diagnosed with treatment-resistant depression (trd)
Where?
- • Antrim - Site 7419
- • Birmingham - Site 7411
- • Bristol - Site 7414
- • Cardiff - Site 7412
- • +6 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 75 Years
- Who can join: All genders
What the study is looking for
- ✓Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF.
- ✓Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of...
- ✓Failure to respond (\<50% improvement) to at least 2-5 antidepressant treatments (including the current treatment)
- ✓Currently taking a stable dose of at least 1 but no more than 2 oral antidepressants at baseline
Who cannot take part
- ✗Evidence of unstable medical condition
- ✗Concurrent use of any prohibited medications or substance use disorder
- ✗Diagnosed bipolar disorder or a psychotic disorder or symptoms
- ✗Significant current PTSD symptoms or history of PTSD
- ✗Clinically significant current impulse control difficulties
See the full criteria
Where Is This Study? (10 UK sites)
Site 7419
Antrim, United Kingdom
Site 7411
Birmingham, United Kingdom
Site 7414
Bristol, United Kingdom
Site 7412
Cardiff, United Kingdom
Site 7418
Exeter, United Kingdom
Site 7415
London, United Kingdom
Site 7413
Nottingham, United Kingdom
Site 7410
Oxford, United Kingdom
Site 7402
Prescot, United Kingdom
Site 7416
Sheffield, United Kingdom
How to Get in Touch
Alto Neuroscience
Sponsor contactCONTACT